Literature DB >> 22521499

Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.

Takaki Kiritoshi1, Hao Sun, Wenjie Ren, Shaun R Stauffer, Craig W Lindsley, P Jeffrey Conn, Volker Neugebauer.   

Abstract

The medial prefrontal cortex (mPFC) serves executive cognitive functions such as decision-making that are impaired in neuropsychiatric disorders and pain. We showed previously that amygdala-driven abnormal inhibition and decreased output of mPFC pyramidal cells contribute to pain-related impaired decision-making (Ji et al., 2010). Therefore, modulating pyramidal output is desirable therapeutic goal. Targeting metabotropic glutamate receptor subtype mGluR5 has emerged as a cognitive-enhancing strategy in neuropsychiatric disorders, but synaptic and cellular actions of mGluR5 in the mPFC remain to be determined. The present study determined synaptic and cellular actions of mGluR5 to test the hypothesis that increasing mGluR5 function can enhance pyramidal cell output. Whole-cell voltage- and current-clamp recordings were made from visually identified pyramidal neurons in layer V of the mPFC in rat brain slices. Both the prototypical mGluR5 agonist CHPG and a positive allosteric modulator (PAM) for mGluR5 (VU0360172) increased synaptically evoked spiking (E-S coupling) in mPFC pyramidal cells. The facilitatory effects of CHPG and VU0360172 were inhibited by an mGluR5 antagonist (MTEP). CHPG, but not VU0360172, increased neuronal excitability (frequency-current [F-I] function). VU0360172, but not CHPG, increased evoked excitatory synaptic currents (EPSCs) and amplitude, but not frequency, of miniature EPSCs, indicating a postsynaptic action. VU0360172, but not CHPG, decreased evoked inhibitory synaptic currents (IPSCs) through an action that involved cannabinoid receptor CB1, because a CB1 receptor antagonist (AM281) blocked the inhibitory effect of VU0360172 on synaptic inhibition. VU0360172 also increased and prolonged CB1-mediated depolarization-induced suppression of synaptic inhibition (DSI). Activation of CB1 with ACEA decreased inhibitory transmission through a presynaptic mechanism. The results show that increasing mGluR5 function enhances mPFC output. This effect can be accomplished by increasing excitability with an orthosteric agonist (CHPG) or by increasing excitatory synaptic drive and CB1-mediated presynaptic suppression of synaptic inhibition ("dis-inhibition") with a PAM (VU0360172). Therefore, mGluR5 may be a useful target in conditions of impaired mPFC output. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521499      PMCID: PMC3568505          DOI: 10.1016/j.neuropharm.2012.03.024

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  94 in total

Review 1.  Presynaptic modulation by endocannabinoids.

Authors:  David M Lovinger
Journal:  Handb Exp Pharmacol       Date:  2008

2.  Reciprocal patterns of c-Fos expression in the medial prefrontal cortex and amygdala after extinction and renewal of conditioned fear.

Authors:  Ewelina Knapska; Stephen Maren
Journal:  Learn Mem       Date:  2009-07-24       Impact factor: 2.460

Review 3.  Changing fear: the neurocircuitry of emotion regulation.

Authors:  Catherine A Hartley; Elizabeth A Phelps
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 4.  Neuronal circuits of fear extinction.

Authors:  Cyril Herry; Francesco Ferraguti; Nicolas Singewald; Johannes J Letzkus; Ingrid Ehrlich; Andreas Lüthi
Journal:  Eur J Neurosci       Date:  2010-02-11       Impact factor: 3.386

5.  Effects of the metabotropic glutamate receptor agonist, ACPD, on the extracellular concentrations of GABA and acetylcholine in the prefrontal cortex of the rat during the normal process of aging.

Authors:  Gregorio Segovia; Francisco Mora
Journal:  Brain Res Bull       Date:  2005-02-15       Impact factor: 4.077

6.  Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior.

Authors:  Zhen Li; Guangchen Ji; Volker Neugebauer
Journal:  J Neurosci       Date:  2011-01-19       Impact factor: 6.167

7.  The role of prefrontal cortex CB1 receptors in the modulation of fear memory.

Authors:  Hui-Ching Lin; Sheng-Chun Mao; Chun-Lin Su; Po-Wu Gean
Journal:  Cereb Cortex       Date:  2008-05-13       Impact factor: 5.357

8.  Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro.

Authors:  Z Z Pan; J T Williams; P B Osborne
Journal:  J Physiol       Date:  1990-08       Impact factor: 5.182

Review 9.  Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Molecules       Date:  2011-03-02       Impact factor: 4.411

10.  Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain.

Authors:  Kathryn Hefner; Nigel Whittle; Jaynann Juhasz; Maxine Norcross; Rose-Marie Karlsson; Lisa M Saksida; Timothy J Bussey; Nicolas Singewald; Andrew Holmes
Journal:  J Neurosci       Date:  2008-08-06       Impact factor: 6.167

View more
  25 in total

1.  CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  Eur J Neurosci       Date:  2014-02       Impact factor: 3.386

2.  Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area.

Authors:  Brittany Draycott; Michael Loureiro; Tasha Ahmad; Huibing Tan; Jordan Zunder; Steven R Laviolette
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 3.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

4.  mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex.

Authors:  Amber L LaCrosse; Sara B Taylor; Natali E Nemirovsky; Justin T Gass; Michael F Olive
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

5.  Top-Down Cortical Control of Acute and Chronic Pain.

Authors:  Louise Urien; Jing Wang
Journal:  Psychosom Med       Date:  2019 Nov/Dec       Impact factor: 4.312

6.  Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors.

Authors:  Wenjie Ren; Takaki Kiritoshi; Stéphanie Grégoire; Guangchen Ji; Remo Guerrini; Girolamo Calo; Volker Neugebauer
Journal:  J Neurophysiol       Date:  2013-07-24       Impact factor: 2.714

7.  Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex.

Authors:  Takaki Kiritoshi; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2015-04-22       Impact factor: 5.250

Review 8.  The function of metabotropic glutamate receptors in thalamus and cortex.

Authors:  S Murray Sherman
Journal:  Neuroscientist       Date:  2013-03-04       Impact factor: 7.519

9.  Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure.

Authors:  R J McLaughlin; M N Hill; S S Dang; S R Wainwright; L A M Galea; C J Hillard; B B Gorzalka
Journal:  Behav Brain Res       Date:  2012-10-06       Impact factor: 3.332

10.  Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator.

Authors:  Marie Pollard; Jose Manuel Bartolome; P Jeffrey Conn; Thomas Steckler; Hamdy Shaban
Journal:  J Psychopharmacol       Date:  2014-07-16       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.